|
|||||
|
|
|
|
|
|
 |
|
 |
|
|
|||||||||||
| Track 1 | Dosing, scheduling and tolerability of the multikinase inhibitors |  |
|||||||||
| Track 2 | Development of bevacizumab for RCC | |
|||||||||
| Track 3 | Balancing benefits and toxicities of targeted agents in the treatment of mRCC | |
|||||||||
| Track 4 | Interactive effect of interferon alpha-2b and bevacizumab on toxicity and efficacy | |
|||||||||
| Track 5 | Role of risk stratification in therapy selection for mRCC |
|
|||||||||
| Track 6 | Effectiveness of the mTOR inhibitor temsirolimus in poor-risk mRCC | |
|||||||||
| Track 7 | Side effects of temsirolimus | |
|||||||||
| Track 8 | Clinical implications of pneumonitis associated with mTOR inhibitors | |
|||||||||
| Track 9 | Tolerability of temsirolimus in patients with previously treated disease | |
|||||||||
| Track 10 | Efficacy of temsirolimus in good-risk RCC | |
|||||||||
| Track 11 | Anti-angiogenic activity of temsirolimus | |
|||||||||
| Track 12 | Clinical algorithm for the treatment of mRCC | |
|||||||||
| Track 13 | Rationale and caveats for combining biologic agents in RCC | |
|||||||||
| Track 14 | Toxicities observed with bevacizumab/interferon alpha-2b | |
|||||||||
| Track 15 | Mechanisms and management of anti-VEGF-associated hypertension | |
|||||||||
| Track 16 | Management of bevacizumab-associated proteinuria | |
|||||||||
| Track 17 | Bevacizumab and epistaxis | |
|||||||||
| Track 18 | Potential direct antitumor effects of anti-VEGF targeted therapies | |
|||||||||
|
|||||||||||
| Track 1 | Risk-benefit considerations in comparing bevacizumab/interferon to sunitinib and sorafenib | |
|||||||||
| Track 2 | Second-line therapy after sunitinib | |
|||||||||
| Track 3 | Tolerability of sunitinib or sorafenib | |
|||||||||
| Track 4 | Study of intrapatient dose-escalated sorafenib for patients with mRCC | |
|||||||||
| Track 5 | Hypertension associated with bevacizumab/TKI combination therapy in clinical trials | |
|||||||||
| Track 6 | Rationale for investigating the combination of mTOR inhibitors and TKIs |
|
|||||||||
| Track 7 | Relationship between dosing and scheduling of the TKIs and therapeutic efficacy | |
|||||||||
| Track 8 | TKI-associated hypothyroidism in RCC | |
|||||||||
| Track 9 | Clinical trial of sunitinib/interferon alpha-2a and erlotinib in papillary RCC | |
|||||||||
| Track 10 | Systemic therapy for papillary RCC | |
|||||||||
| Track 11 | Proportion of patients with RCC treated with adjuvant therapy | |
|||||||||
| Track 12 | Historical evolution of adjuvant clinical trials in RCC | |
|||||||||
| Track 13 | Patterns of tumor progression in RCC | |
|||||||||
| Track 14 | Patient acceptance of long-term adjuvant therapy with biologic agents | |
|||||||||
| Track 15 | Time course of recurrence in RCC | |
|||||||||
| Track 16 | Role of nephrectomy in mRCC | |
|||||||||
| Track 17 | Wound-healing issues with biologic agents in RCC | |
|||||||||
| Track 18 | Role of interleukin-2 in RCC | |
|||||||||
|
|||||||||||
| Track 1 | Temsirolimus, interferon alpha or the combination as first-line therapy for poor-risk mRCC | |
|||||||||
| Track 2 | Potential mechanism of action of temsirolimus in RCC | |
|||||||||
| Track 3 | AVOREN trial: Interferon alpha-2a with or without bevacizumab as first-line therapy for mRCC | |
|||||||||
| Track 4 | Bevacizumab monotherapy and stable disease | |
|||||||||
| Track 5 | Challenges in evaluating combination biologic therapies in RCC | |
|||||||||
| Track 6 | Clinical algorithm for the treatment of mRCC |
|
|||||||||
| Track 7 | Side effects and tolerability of interleukin-2 | |
|||||||||
| Track 8 | Potential mechanisms of action of immunotherapy in RCC | |
|||||||||
| Track 9 | Use of bevacizumab monotherapy | |
|||||||||
| Track 10 | Dose adjustments and management of toxicity in patients undergoing targeted therapies | |
|||||||||
| Track 11 | Selection of second-line therapy in mRCC | |
|||||||||
| Track 12 | New developments in the management of TKI-associated hand-foot syndrome | |
|||||||||
| Track 13 | Dose reductions to manage TKI-associated toxicities | |
|||||||||
| Track 14 | Dose escalation of sorafenib in mRCC | |
|||||||||
| Track 15 | Ongoing adjuvant trials in RCC |
|
|||||||||
| Track 16 | Use of chemotherapy for patients with rapidly progressing mRCC | |
|||||||||
| Track 17 | Case discussion: A septuagenarian with small, bilateral mRCC lung nodules and subsequent brain metastases with rapid symptom relief from sunitinib | |
|||||||||
| Track 18 | Management of the primary tumor in patients with concurrent mRCC | |
|||||||||
 |
Terms of Use and General Disclaimer | Privacy Policy Copyright © 2008 Research To Practice. All Rights Reserved. |
 |
